Last reviewed · How we verify
Daridorexant 50 mg
At a glance
| Generic name | Daridorexant 50 mg |
|---|---|
| Also known as | Quviviq, QUVIVIQ |
| Sponsor | Legacy Health System |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Dual Orexin Antagonism and Emotion and Affective Processing Study (PHASE4)
- Comparing Digital Therapy, Trazodone, and Daridorexant for Menopause-Related Insomnia Symptoms (PHASE4)
- Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Daridorexant in Subjects Aged 10 to < 18 Years With Insomnia Disorder (PHASE2)
- Impact of Daridorexant on Sleep, Daytime Alertness, and Smoking (PHASE4)
- Daridorexant to Prevent Post-cardiotomy Delirium (PHASE2)
- Daridorexant for Alzheimer Disease Prevention (PHASE2)
- Department of Defense PTSD Adaptive Platform Trial - Intervention C - Daridorexant (PHASE2)
- Department of Defense PTSD Adaptive Platform Trial - Master Protocol (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Daridorexant 50 mg CI brief — competitive landscape report
- Daridorexant 50 mg updates RSS · CI watch RSS
- Legacy Health System portfolio CI